After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)

Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown)... More

Immunomedics (IMMU) Prices 14.286M Share Common Offering at $17.50/Sh

Immunomedics, Inc. (NASDAQ: IMMU) today announced the pricing of an... More

SunTrust Reiterates Buy Rating on Zscaler (ZS) Following 1Q Beat

SunTrust analyst Joel Fishbein Jr. reiterated a Buy rating and $73.00 price target on Zscaler (NASDAQ: ZS) following the company's 1Q earnings report. Zscaler delivered a slight beat and raise with margin upside.

The Company reported $93.6MM of revenue for 1Q20, beating consensus at... More

Raptor Technology Group, Inc. (RAPT) Announces Rodney Young as CFO

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.

As a newly public company, we are thrilled to welcome Rodney to RAPT, said Brian Wong, M.D., Ph.D., president and CEO of RAPT... More

Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of... More

Relmada Therapeutics (RLMD) Prices 3.33M Share Common Offering at $33/Sh

Relmada Therapeutics, Inc. (NASDAQ: RLMD) today announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and... More